News & Updates

The oral selective Janus kinase 1/2 inhibitor baricitinib, when added to standard of care (SoC), reduced the risk of mortality among adults hospitalized with COVID-19. However, the primary outcome of disease progression was not met in the baricitinib group, results of the phase III COV-BARRIER study showed.

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Chronic obstructive pulmonary disease (COPD) patients who have concomitant rhinosinusitis without nasal polyps (RSsNP) face more psychological issues, higher COPD symptom burden, and poorer overall quality of life (QoL), according to a study.

In the treatment of patients with severe, uncontrolled asthma, use of tezepelumab appears to produce rapid and sustained improvements in lung function, as reported in a study.

A 3-day course of remdesivir may help stave off COVID-19–related hospitalization and death, according to results of the phase III PINETREE study.

Hospitalized patients with COVID-19 who receive antiplatelet and anticoagulant drugs concurrently may fare better than those given only therapeutic anticoagulation, according to a study.